MAP2K7 and neoplasm: Other studies have defined adaptive kinome reprogramming in different tumor types (e.g., renal cell carcinoma, ovarian cancer, leukemia, glioblastoma lymphoma) and with inhibitors targeting kinases in pathways different from the MEK-ERK pathway such as targeting inhibition of the PI3K-AKT pathway (11, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40).